Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer

• Published in: Zhong hua yi xue za zhi Vol. 91; no. 47; p. 3367
• Main Authors: Xin, Gang, Du, Juan, Zhu, Lin, Yu, Yun-hai, Li, Yue, Liu, Pei-shu
• Format: Journal Article
• Language: Chinese
• Published: China 20.12.2011
• Subjects: Actins - analysis; Animals; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cisplatin - administration & dosage; Collagen Type IV - analysis; Endostatins - administration & dosage; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Ovarian Neoplasms - drug therapy; Proliferating Cell Nuclear Antigen - analysis; Xenograft Model Antitumor Assays
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2011.47.014

To find the time window of normalization of tumor vasculature by endostar in tumor-bearing mice with ovarian cancer. The nude murine model of ovarian cancer was established. The vasculature markers α-SMA (alpha-smooth muscle actin) and collagen IV covered tumor vessels and hypoxic zone following the treatment of endostar were monitored. According to the changes of microvascular morphology and tumor hypoxia zone, the time window was identified. Furthermore the treatment protocols of scheduling dosing of cisplatin plus endostar at different time points were designed. After treatment tumor volume, the parameters of microvascular density (MVD) and PCNA (proliferating cell nuclear antigen) were monitored to evaluate the effects of different protocols. At Days 4 and 6 post-treatment, more α-SMA and collagen IV covered vessels could be observed. The amount of microvasculature expressed α-SMA on days 4 compared with control was (15.3 ± 5.2) vs (4.3 ± 2.1)/mm(2) (P < 0.01); at Day 6, the result was (16.4 ± 4.6) vs (6.